Efficacy and Safety of Lumiracoxib in Patients With Primary Knee Osteoarthritis (OA)

Inclusion Criteria: * Any patient who completed the core study 2361 may enter the extension trial upon signing informed consent. A patient is defined as completing if he/she completed the core study 2361 up to and including Visit 6 (week 13) without a major protocol violation. Exclusion Criteria: * Those patients for whom continued treatment in the extension study is not considered appropriate by the treating physician * Those patients who were non-compliant or who demonstrated a major protocol violation in the core study. Other protocol-defined inclusion/exclusion criteria may apply